<DOC>
	<DOC>NCT00705484</DOC>
	<brief_summary>This is a prospective, safety surveillance registry in subjects with moderate-to-severe active ulcerative colitis (UC).</brief_summary>
	<brief_title>European Safety Registry in Ulcerative Colitis (Study P04808AM3)</brief_title>
	<detailed_description>This is a prospective, observational, post-marketing safety surveillance registry of UC subjects treated with Remicade or another standard therapy. Registry centers are targeted to enroll a total of 2000 subjects (1000 Remicade subjects and 1000 standard therapy subjects) and to follow them for a period of up to 5 years. Subjects who started the registry on standard therapy may switch over to Remicade.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>18 years of age, of either sex, and of any race. Moderatetosevere active UC, as defined by assessment by the treating physician. Must, within 30 days of Baseline, either: Initiate or have a dose increase of immunosuppressive drug(s), including but not limited to systemic steroids (budesonide is considered a topical steroid), azathioprine (AZA), or methotrexate (subjects in this category must be Remicade na√Øve) or Initiate Remicade. Subjects who have been treated in the past with Remicade, but who have discontinued for any reason and who are scheduled to receive Remicade within 30 days of the baseline visit must have a Remicadefree interval of no less than 90 days from the date of the next expected infusion Must be willing to give written informed consent and must be able to adhere to the procedural requirements of the registry. Must be evaluated for active and inactive (latent) tuberculosis (TB) as suggested by local guidelines or as required by the Remicade label for subjects starting Remicade. Female who is known to be pregnant or nursing. Previously treated with any other (investigational) biological drug for UC( other than Remicade) prior to Baseline. In a situation or have any condition that, in the opinion of the treating physician, may interfere with their optimal participation in the registry. Participating in a blinded trial. In addition, subjects with conditions that are contraindicated in the Remicade Summary of Product Characteristics (SPC) should not be treated with Remicade.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>